Positive effect of single nucleotide RAD51 135G>C polymorphism and low Ku70 protein expression on female rectal cancer patients survival after preoperative radiotherapy.


Journal

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
ISSN: 2148-5607
Titre abrégé: Turk J Gastroenterol
Pays: Turkey
ID NLM: 9515841

Informations de publication

Date de publication:
01 2019
Historique:
pubmed: 6 10 2018
medline: 23 4 2019
entrez: 6 10 2018
Statut: ppublish

Résumé

This is a retrospective analysis of 103 patients having locally advanced rectal cancer who received short-course radiotherapy (SCRT). The objective of the study was to check whether a polymorphism in the RAD51 gene (135 G>C), Ku70 protein expression, and tumor microenvironment: proliferation rate measured by BrdUrdLI and Ki-67LI, hypoxia (glucose transporter-1 expression), P53 protein expression, and DNA ploidy can influence DNA repair capacity, the factors contributing to patient overall survival (OS) and the incidence of recurrences and metastases. RAD51 (135 G>C) polymorphism was evaluated using restriction fragment length polymorphism polymerase chain reaction, and proteins were identified using immunohistochemistry. There were 3 (2.9%) tumors with RAD51 CC, 75 (72.8%) with GG, and 25 (24.3%) with GC genotypes. The median follow-up time was 63.1 months (range 2-120). Patients with CC genotype survived significantly longer than those with GG and GC genotypes and did not develop any recurrences or distant metastases. Female patients with Ku70 expression (<75.1) or RAD51CC genotype (impaired DNA damage repair and radiosensitive) had significantly longer OS (p=0.013) than those with Ku70>75.1 % or RAD51GG,GC (radioresistant phenotype) and male patients in the log-rank test. In multivariate analysis, positive prognostic factors for OS in the male patients were grade=1 and <17 days break in the treatment, whereas in the female subgroup, only radiosensitive phenotype (Ku70 <75.1% or RAD51CC genotype). To the best of our knowledge, this is the first study to provide evidence for the positive effect of CC genotype of RAD51 or low Ku70 expression on OS in females with rectal cancer after SCRT.

Sections du résumé

BACKGROUND/AIMS
This is a retrospective analysis of 103 patients having locally advanced rectal cancer who received short-course radiotherapy (SCRT). The objective of the study was to check whether a polymorphism in the RAD51 gene (135 G>C), Ku70 protein expression, and tumor microenvironment: proliferation rate measured by BrdUrdLI and Ki-67LI, hypoxia (glucose transporter-1 expression), P53 protein expression, and DNA ploidy can influence DNA repair capacity, the factors contributing to patient overall survival (OS) and the incidence of recurrences and metastases.
MATERIALS AND METHODS
RAD51 (135 G>C) polymorphism was evaluated using restriction fragment length polymorphism polymerase chain reaction, and proteins were identified using immunohistochemistry.
RESULTS
There were 3 (2.9%) tumors with RAD51 CC, 75 (72.8%) with GG, and 25 (24.3%) with GC genotypes. The median follow-up time was 63.1 months (range 2-120). Patients with CC genotype survived significantly longer than those with GG and GC genotypes and did not develop any recurrences or distant metastases. Female patients with Ku70 expression (<75.1) or RAD51CC genotype (impaired DNA damage repair and radiosensitive) had significantly longer OS (p=0.013) than those with Ku70>75.1 % or RAD51GG,GC (radioresistant phenotype) and male patients in the log-rank test. In multivariate analysis, positive prognostic factors for OS in the male patients were grade=1 and <17 days break in the treatment, whereas in the female subgroup, only radiosensitive phenotype (Ku70 <75.1% or RAD51CC genotype).
CONCLUSION
To the best of our knowledge, this is the first study to provide evidence for the positive effect of CC genotype of RAD51 or low Ku70 expression on OS in females with rectal cancer after SCRT.

Identifiants

pubmed: 30289394
doi: 10.5152/tjg.2018.17486
pmc: PMC6389307
doi:

Substances chimiques

Rad51 Recombinase EC 2.7.7.-
Ku Autoantigen EC 4.2.99.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3-14

Références

Genes Dev. 1999 Apr 15;13(8):916-34
pubmed: 10215620
Nature. 1999 Apr 22;398(6729):665, 667
pubmed: 10227286
Oncogene. 1999 Jun 17;18(24):3553-63
pubmed: 10380877
Lancet. 2000 May 20;355(9217):1745-50
pubmed: 10832824
Science. 2001 Feb 16;291(5507):1284-9
pubmed: 11181991
Nat Genet. 2001 Mar;27(3):247-54
pubmed: 11242102
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3232-6
pubmed: 11248061
Toxicology. 2003 Nov 15;193(1-2):91-109
pubmed: 14599770
Eur J Gynaecol Oncol. 2005;26(6):589-98
pubmed: 16398215
Trends Genet. 2006 Mar;22(3):119-22
pubmed: 16430990
Mutat Res. 2006 Oct 10;601(1-2):83-91
pubmed: 16843501
J Gastrointest Surg. 2007 Apr;11(4):520-8
pubmed: 17436139
Am J Hum Genet. 2007 Dec;81(6):1186-200
pubmed: 17999359
Breast Cancer Res Treat. 2011 Feb;125(3):827-35
pubmed: 20640595
Mol Biol Rep. 2011 Apr;38(4):2849-54
pubmed: 21104022
J Gastrointest Surg. 2011 Sep;15(9):1568-76
pubmed: 21706276
Pol J Pathol. 2012 Nov;63(3):193-8
pubmed: 23161237
Radiother Oncol. 2014 Jan;110(1):195-8
pubmed: 24286634
J Gastrointest Surg. 2014 Jul;18(7):1306-18
pubmed: 24756926
Mol Cancer Res. 2014 Oct;12(10):1407-15
pubmed: 25030372
PLoS One. 2014 Sep 23;9(9):e108562
pubmed: 25247297
Am J Clin Oncol. 2017 Dec;40(6):535-542
pubmed: 25811296
Radiother Oncol. 2015 Sep;116(3):388-91
pubmed: 25842967
Radiother Oncol. 2016 May;119(2):236-43
pubmed: 26987471
Rep Pract Oncol Radiother. 2017 Sep-Oct;22(5):368-377
pubmed: 28794690
Nature. 2017 Dec 7;552(7683):116-120
pubmed: 29186113
EMBO J. 1996 Apr 15;15(8):1992-2002
pubmed: 8617246
EMBO J. 1998 Sep 15;17(18):5497-508
pubmed: 9736627

Auteurs

Anna Gasinska (A)

Department of Applied Radiobiology, Maria Sklodowska - Curie Institute, Oncology Center, Cracow Branch, Poland.

Beata Biesaga (B)

Department of Applied Radiobiology, Maria Sklodowska - Curie Institute, Oncology Center, Cracow Branch, Poland.

Anna Janecka Widla (AJ)

Department of Applied Radiobiology, Maria Sklodowska - Curie Institute, Oncology Center, Cracow Branch, Poland.

Zbigniew Darasz (Z)

Department of Surgery, Maria Sklodowska - Curie Institute, Oncology Center, Cracow Branch, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH